EST4E Non-invasive Preimplantation Genetic Screening (PGS) testing for IVF patient embryos that are not suitable for standard biopsy to determine the proportion of embryos that are unable to be screened using standard PGS that can be conclusively screened for aneuploidy using NEST4E by analysing cell-free DNA in the embryo culture media.

Repromed0 个研究点目标入组 73 人开始时间: 2018年6月26日最近更新: 2019年1月28日

适应症

试验速览

暂无简介。

•1.Any patient for whom PGS is considered as a treatment option will be eligible
•2.Patients that have blastocysts’ that are not suitable for standard biopsy and PGS.
•Under the current Ethical guidelines on the use of assisted reproductive technology in clinical practice and research (2017), only patients that have already consented to the use of PGT to select against a genetic condition, disease or abnormality will be approached in this study. This is to recognise that the decision to have genetic testing requires serious ethical consideration and is to prevent patients consenting to this trial to access this technology without having considered the full ethical implications.

•1.Patients involved in the Donor program (oocyte and sperm)
•2.Patients with a known infectious disease (HIV, HEP B, HEP C)
•3.Patients using Preimplantation Genetic Diagnosis (PGD) for single genes or translocations.

发起方

Repromed